Welcome to Rx Dynamics: where compound interaction testing becomes easy
We are the diagnostics company behind CombiANT a new technology that streamlines compound interaction testing. Bioactive compounds such as antibiotics, pesticides, fungicides, and chemotherapeutics do not always act alone. Multiple drugs are often combined in the hopes of getting greater effects. The components of a drug combination though, often interact with each other, either enhancing (synergy) or counteracting (antagonism) individual effects. Identifying the nature of their interaction is paramount for the combination’s success. That’s why we developed CombiANT: an assay capable of detecting synergies and antagonisms on 3 compound combinations at the same time!
CombiANT: the petri dish 2.0
Handles as easily as a petri dish, but provides a wealth of information
Test for compound interactions easily!
Detect and quantify compound antagonisms and synergies using technology as simple as a petri dish !
Try out CombiANT
Our product is currently undergoing its last stage of development, We have opened access to it to labs from around the world that are willing to try it out in the form of a BETA test. Join the BETA test and help us develop the interaction testing product of the future according to your needs.
Join the closed BETA test of CombiANT!
Become a part of an expanding list of research labs across the world that are trying out CombiANT in their own research !
The Team
Dr. Nikos Fatsis-Kavalopoulos CEO/co-founder
Biomedical Engineer specializing in novel diagnostics development
Dr. Eva Garmendia COO
Microbiologist specializing in antibiotic resistance and scientific project management and communication
Dr. Po-Cheng Tang co-founder
Microbiologist specializing in innovation
Dr. Roderich Römhild scientist/co-founder
Evolutionary microbiologist with a background in antibiotic combinations
Prof. Johan Kreuger co-founder
Cell biologist developing methods for drug testing and cell signaling studies
Prof. Dan Andersson co-founder
Bacterial geneticist and evolutionary biologist working on drug resistance and evolution of new genes
Scientific Studies
Within-species variability of antibiotic interactions in Gram-negative bacteria
Full study on mBio Treatments with antibiotic combinations are becoming increasingly important even though the supposed clinical benefits of combinations are, in many cases, unclear. Here, we systematically examined how several clinically used antibiotics interact and affect the antimicrobial efficacy against five especially problematic Gram-negative pathogens. A total of 232 bacterial isolates were tested against …
Continue reading “Within-species variability of antibiotic interactions in Gram-negative bacteria”
Potential risks of treating bacterial infections with a combination of β-lactam and aminoglycoside antibiotics: A systematic quantification of antibiotic interactions in E. coli blood stream infection isolates
Full study on Lancet eBioMedicine Treatment of Blood Stream Infections (BSIs) with a combination of a β-lactam and an aminoglycoside antibiotic is widely used in intensive care units (ICUs) around the world. However, no studies have systematically examined how these drugs interact and potentially influence the antimicrobial efficacy of the overall treatment. We collected 500 …
CombiANT: Antibiotic interaction testing made easy
Full study on PLOS Biology Antibiotic combination therapies are important for the efficient treatment of many types of infections, including those caused by antibiotic-resistant pathogens. Combination treatment strategies are typically used under the assumption that synergies are conserved across species and strains, even though recent results show that the combined treatment effect is determined by …
Continue reading “CombiANT: Antibiotic interaction testing made easy”
Partners
With support from
